welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Cancer Prevention Pharmaceuticals Completes Target Enrollment in Pivotal Phase 3 Clinical Trial Evaluating CPP-1X/sulindac in Patients with Familial Adenomatous Polyposis
Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today that target enrollment has been achieved for the company’s pivotal Phase 3 clinical trial, CPP FAP-310, evaluating CPP-1X/sulindac in adults with familial adenomatous polyposis (FAP).
expertly curated content related to this topic
-
Shrinking the SilenceI’m a 28 year old, living with two ver...
-
A Randomised, Double Blind, Placebo Controlled Study of Celecoxib, a Selective Cyclooxygenase 2 Inhibitor, on Duoden...BACKGROUND : Non-selective cyclooxygenas...
-
An International Randomised Trial of Celecoxib versus Celecoxib plus Difluoromethylornithine in Patients with Famili...BACKGROUND AND AIM : Although Non-steroi...
-
Clinical Management of Adenomatous Polyposis in Patients with Hereditary Non-Polyposis Colorectal Cancer and Familia...OBJECTIVE : To investigate the validity ...
-
Detection of Epithelial Apoptosis in Pelvic Ileal Pouches for Ulcerative Colitis and Familial Adenomatous PolyposisBACKGROUND : Ileal pouch-anal anastomosi...
-
Prospective Randomized Study of Sulindac versus Calcium and Calciferol for Upper Gastrointestinal Polyps in Familial...Eighteen patients with familial adenomat...
-
Pancreatic Enzyme Replacement TherapyIf you have chronic pancreatitis, a panc...